However, because most doctors do not watch the patient's blood sugar remain high, most of them will adjust the drug before the glycated hemoglobin exceeds the standard but does not reach 8.5%, resulting in a huge gap between the health insurance payment threshold and the clinical situation, so that people with diabetes can see But it doesn't work. Glycated hemoglobin conversion average blood sugar level Normal blood sugar control target: fasting blood glucose 130 mg/dL, postprandial blood glucose 160-180 mg/dL, glycosylated hemoglobin below 7% (the control target will vary slightly according to different ages and clinical conditions).
When the glycosylated hemoglobin is 8.5%: the old picture restoration average blood sugar is above 200 mg/dL, which is equivalent to fasting blood sugar close to 200 mg/dL, postprandial blood sugar 250-260 mg/dL, and such a value is far from the recommended target. Dr. Li Hongyuan pointed out that those who do not meet the above-mentioned health insurance payment standards must use incretin at their own expense, which will cost an average of 3,000 to 4,000 yuan per month, not including outpatient registration, diagnosis and treatment, care and other related expenses, which accumulate over a long period of time.
The amount is considerable. Therefore, under the current health insurance payment conditions, many people with diabetes are unable to use incretin therapy as soon as possible due to financial constraints, even if their blood sugar is not well controlled, further increasing the risk of cardio-renal comorbidities. This result is not only a big blow to diabetes control, but also does not help to reduce the overall health care financial expenditure in the long run. Payback in 3 years! Diabetes Care Foundation: Looking forward to repairing the payment conditions of incretin health insurance to create a win-win situation Regarding this situation,